10-Q: InnovAge Reports Q3 2025 Results: Revenue Up 13%, Loss Narrows Amidst Cost Management Efforts

InnovAge Holding Corp. reports a 13% increase in revenue for Q3 2025, driven by growth in PACE program participants and capitation rates, while continuing to manage costs and navigate regulatory challenges.

Summary

• InnovAge Holding Corp. reported a net loss of $11.13 million for the three months ended March 31, 2025, compared to a net loss of $6.18 million for the same period in 2024.
• Total revenue increased by 13% to $218.14 million, driven by a rise in capitation revenue due to increased participant numbers and capitation rates.
• The company served approximately 7,530 PACE participants as of March 31, 2025, operating 20 PACE centers across six states.
• External provider costs increased by 7.9% to $107.9 million, while cost of care, excluding depreciation and amortization, rose by 17.6% to $69.5 million.
• Corporate, general, and administrative expenses increased significantly by 40.1% to $38.6 million, primarily due to an accrual for a stockholder lawsuit settlement.
• The company recorded an impairment of right-of-use assets and construction in progress totaling $8.5 million related to a halted de novo center development.
• Adjusted EBITDA increased to $10.79 million, compared to $2.96 million in the prior year, reflecting improved cost management and revenue growth.
• The company repurchased 314,926 shares of its common stock for approximately $1.1 million during the quarter.
• InnovAge is managing ongoing civil investigative demands from the Attorney General for the State of Colorado and the Department of Justice.
• The company is addressing processing delays and eligibility gaps in California by increasing the proportion of new enrollments submitted prior to the first enrollment deadline each month.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. Revenue growth and improved Adjusted EBITDA are positive, but increased net losses, higher administrative expenses, and ongoing legal challenges temper the outlook. The sentiment is neutral, reflecting both positive and negative developments.

Positives

• Revenue increased by 13% to $218.14 million for the three months ended March 31, 2025, driven by growth in PACE program participants and capitation rates.
• Adjusted EBITDA increased to $10.79 million, compared to $2.96 million in the prior year, reflecting improved cost management and revenue growth.
• The company repurchased 314,926 shares of its common stock for approximately $1.1 million during the quarter.
• External provider costs decreased by 2.5% in cost per participant for the three months ended March 31, 2025 as compared to the three months ended March 31, 2024.

Negatives

• Net loss increased to $11.13 million for the three months ended March 31, 2025, compared to a net loss of $6.18 million for the same period in 2024.
• Corporate, general, and administrative expenses increased significantly by 40.1% to $38.6 million, primarily due to an accrual of $10.7 million for a stockholder lawsuit settlement.
• The company recorded an impairment of right-of-use assets and construction in progress totaling $8.5 million related to a halted de novo center development in Louisville, Kentucky.

Risks

• The company is managing ongoing civil investigative demands from the Attorney General for the State of Colorado and the Department of Justice.
• The company is addressing processing delays and eligibility gaps in California, which could impact revenue.
• The healthcare sector continues to experience challenges in hiring additional professionals, leading to wage pressure.
• Macroeconomic trends, such as tariffs and trade tensions, may result in higher prices for medical supplies and supply chain disruptions.
• The company's ability to grow enrollment and capacity within existing centers can be affected by sanctions issued by regulators or suspensions of State attestations required to open new de novo centers.

Future Outlook

The company expects to continue experiencing increased cost of care per participant in fiscal year 2025, partially as a result of increased salaries, wages and benefits. The company believes that its clinical value initiatives and operational value initiatives, which continue to be developed, may assist it in offsetting the increasing cost of care.

Management Comments

• The company is focused on providing all-inclusive care to frail, high-cost, dual-eligible seniors.
• The company is strengthening its expanding payer capabilities so that its revenue more accurately reflects the acuity of the populations it serves.
• The company is investing to increase its sophistication as a payor to drive clinical value, improve outcomes, and manage cost trends.

Industry Context

The PACE program addresses the growing need for comprehensive care for the elderly, particularly those who are dual-eligible for Medicare and Medicaid. The company faces competition from other healthcare providers, including Medicare Advantage plans, and must navigate complex regulatory requirements and government payor relationships.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• A full comparison would require benchmarking InnovAge's key financial metrics (revenue growth, cost of care, EBITDA margin) against those of its direct competitors in the PACE market, such as Element3 Health, WelbeHealth, and CenterWell Senior Primary Care.
• Additionally, comparing InnovAge's participant satisfaction and retention rates to industry averages would provide valuable insights.
• Finally, assessing InnovAge's regulatory compliance record and its ability to manage risk relative to its peers is crucial for a comprehensive evaluation.

Legal Proceedings

• The Company continues to fully cooperate with the Attorney General for the State of Colorado regarding a civil investigative demand.
• The Company and the DOJ have begun discussions to understand their respective positions on a civil investigative demand.
• The Company is fully cooperating with the DOJ and producing the requested information and documentation regarding a civil investigative demand related to the Company's relationship as a PACE provider with residential care facilities.
• The Company and the other defendants have entered into a binding term sheet with the plaintiffs agreeing to settle all claims in exchange for a payment by the Company of $27.0 million, subject to entering into final settlement documents and approval by the District Court.
• On May 15, 2023, Mr. Hall filed a lawsuit in the Delaware Court of Chancery asserting derivative claims for breach of fiduciary duty against certain of the Company’s current and former officers and directors.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and the accrual for the stockholder lawsuit settlement.
• Participants in the PACE program may be affected by the company's efforts to manage costs and improve efficiency.
• Employees may be affected by the company's efforts to manage costs and improve efficiency.
• The company's relationships with government payors are critical to its long-term success.

Next Steps

• The company will continue to address processing delays and eligibility gaps in California.
• The company will continue to manage ongoing civil investigative demands from the Attorney General for the State of Colorado and the Department of Justice.
• The company will continue to focus on providing all-inclusive care to frail, high-cost, dual-eligible seniors.
• The company will continue to strengthen its expanding payer capabilities so that its revenue more accurately reflects the acuity of the populations it serves.
• The company will continue investing to increase its sophistication as a payor to drive clinical value, improve outcomes, and manage cost trends.

Key Dates

Keywords

PACE, capitation, revenue, enrollment, Medicaid, Medicare, Adjusted EBITDA, share repurchase, legal proceedings, cost of care